社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Moderna, Inc.(MRNA)
盘后
53.27
0.00
0.00%
19:43 EDT
53.27
+0.39
+0.74%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
投阅笔记
·
05-04
Moderna 2026Q1财报：净亏13亿美元，但2026年目标明确——营收增长10%
$Moderna, Inc.(MRNA)$
2026年5月1日莫德纳（Moderna）今日公布了2026年第一季度的财务业绩并提供了业务进展更新。 先看下概要： 第一季度营收为3.89亿美元，其中约80%来自国际市场 报告第一季度GAAP净亏损为13亿美元，GAAP每股收益为-3.40美元，其中包括9亿美元的非经常性诉讼和解费用 重申计划在2026年实现最高10%的营收增长及GAAP运营费用削减，该数据不包含非经常性诉讼和解费用 传染病产品组合在欧盟取得关键监管里程碑，包括mNEXSPIKE和mCOMBRIAX（Moderna的流感加新冠联合疫苗）获批 启动III期临床研究，评估intismeran autogene作为单药治疗以及与KEYTRUDA QLEX联合治疗高危I期非小细胞肺癌 Moderna首席执行官Stéphane Bancel表示： “莫德纳团队为今年开了一个好头，在2025年采取的措施基础上，实现了显著的营收增长和大幅的成本削减。我们获得了两项欧洲产品批准，其中包括全球首款流感加新冠联合疫苗mCOMBRIAX。此外，我们还启动了intismeran的新关键性试验——这是针对高危1期非小细胞肺癌患者的首项III期单药治疗研究，依托第一季度的强劲势头，我们很高兴能在2026年重回销售增长轨道，并预期在全球范围内获得多项新批准，其中包括我们的季节性流感疫苗——这将成为莫德纳的第五款获批产品。我们也期待今年在诺如病毒、用于黑色素瘤的intismeran以及丙酸血症项目方面取得重要的关键性试验结果。” 商业动态 第一季度，Moderna通过落实战略合作与关键审批，持续推进其多年期营收增长战略。在英国，公司已根据长期战略合作协议完成了首批产品交付。Moderna还获得了欧洲监管机构对mNE
Moderna 2026Q1财报：净亏13亿美元，但2026年目标明确——营收增长10%
精彩
AbnerKeppel:
目标还挺明确，但亏这么多还得看看后续表现。
回复
1
点赞
2
编组 21备份 2
分享
举报
Pan the man
·
04-21
谁是“制药界的SpaceX”？ 在航天史上，SpaceX之所以颠覆行业，并不在于它设计了更多卫星，而在于它重构了“火箭”这一底层系统，使得发射成本大幅下降、成功率显著提升，并最终成为整个产业链的基础设施。 而在生物医药领域，类似的范式正在发生： 以Moderna、Alnylam Pharmaceuticals为代表的企业，已经证明—— 谁掌握递送技术，谁就掌握了新一代制药工业的“发射权”。 在这一背景下，以AI驱动递送系统设计的平台型公司（如剂泰科技），其战略意义正在被迅速重估： 它们不再只是“做药的公司”，而更像是—— 为整个行业提供“发射能力”的底层系统供应商。 一、最接近“SpaceX”的核心标的（递送=火箭） 1.
$Moderna, Inc.(MRNA)$
核心标签：mRNA + LNP递送平台化王者 为什么它是“SpaceX”？ * 核心不是疫苗，而是mRNA + LNP递送系统 * 疫苗只是验证场景，本质是“可编程生物平台” * 类似SpaceX的Falcon 9：一次技术 → 多任务复用 护城河 * 自主LNP体系（摆脱专利依赖） * mRNA设计 + 递送一体化 * 已验证商业化（COVID收入） 投资逻辑 * 正从疫苗公司 → 平台型BioTech * 癌症疫苗、罕见病、心血管都在扩展 * 如果“递送时代”成立，它是最直接受益者 ⸻ 2.
$阿尔尼拉姆制药公司(ALNY)$
核心标签：RNAi + 肝脏递送王者 SpaceX属性 * RNAi本身不是难点，递送才是核心壁垒 * 在肝脏递送领域几乎“垄断级优势” 护城河 * GalN
谁是“制药界的SpaceX”？ 在航天史上，SpaceX之所以颠覆行业，并不在于它设计了更多卫星，而在于它重构了“火箭”这一底层系统，使得发射成本大幅下降...
回复
评论
点赞
1
编组 21备份 2
分享
举报
小虎老师
·
03-09
周评：地缘催化美股连跌两周，油价与VIX飙升，美元与债券收益率反弹
上周回顾 1. 美国市场——地缘政治冲击波驱动避险资金涌入 美国、以色列与伊朗之间的地缘政治紧张局势，以及随之而来的油价飙升，已显著影响市场动态。黄金和白银等避险资产也随之上涨，投资者寻求躲避不确定性。 负面催化剂：受中东冲突、油价上涨以及令人失望的月度就业报告拖累，美股指数连续第二周下跌。
$道琼斯(.DJI)$
2.9%，
$标普500(.SPX)$
回落2.0%，
$纳斯达克(.IXIC)$
收跌1.2%。 新兴市场抛售：避险情绪重创国际股市；MSCI EAFE指数和MSCI新兴市场指数均暴跌近7%。 油价飙升：不断升级的军事冲突席卷中东，推动油价升至2023年9月以来最高水平。 VIX跳涨：
$标普500波动率指数(VIX)$
收于29.5，较前一周收盘水平上涨48%。 美元与收益率逆转：周五，10年期美国国债收益率
$10年美债主连 2606(ZNmain)$
收于4.15%，高于前一周的3.96%。同时，
$美元指数(USDindex.FOREX)$
在避险资金涌入背景下走强。 四季度财报：根据FactSet数据，标普500指数成分股公司公布的平均盈利较上年同期增长14.0%。 通胀观察：投资者本周关键关注消费者物价指数（周三）和个人消费支出物价指数（周五）或将指
周评：地缘催化美股连跌两周，油价与VIX飙升，美元与债券收益率反弹
精彩
Sige heil:
什么意思。美股要涨 大a又…
回复
1
点赞
11
编组 21备份 2
分享
举报
投阅笔记
·
03-05
Moderna发布2025年财报：全年亏损28亿美元，但2026年增长预期达10%
$Moderna, Inc.(MRNA)$
2026年2月13日Moderna公布2025年第四季度财务业绩及业务进展。 业绩概要： 第四季度营收7亿美元，公认会计准则净亏损8亿美元，每股收益亏损2.11美元 全年营收19亿美元，公认会计准则净亏损28亿美元，公认会计准则摊薄每股收益亏损7.26美元 重申2026年营收增长目标达10%，并计划削减GAAP运营支出 宣布流感疫苗获欧盟、加拿大及澳大利亚监管机构受理；美国FDA发出拒收函，公司已申请A类会议商讨后续路径(最新消息已经通过) 诺如病毒三期临床试验完成患者招募，数据读出预计于2026年完成 宣布肌层浸润性膀胱癌II期intismeran自体移植试验完成患者招募 2025年第四季度财务业绩 收入：2025年第四季度总收入达6.78亿美元，处于公司前期预期区间上限，主要由新冠疫苗销售驱动。其中美国市场产品销售额为2.64亿美元，国际市场为3.81亿美元。与2024年同期相比，第四季度收入下降30%，主要反映新冠疫苗销量较上年同期减少。 销售成本：2025年第四季度销售成本为4.52亿美元，包含第三方特许权使用费3400万美元及库存减值1.44亿美元。销售成本较2024年同期下降39%，主要反映合同制造业务收尾成本及库存减值减少。 研发费用：2025年第四季度研发费用为7.75亿美元，较2024年同期下降31%。主要因临床开发及生产成本降低所致，反映出大型III期呼吸系统项目逐步收尾、持续推进产品组合优先级调整以及全公司范围内的成本管控成效。 销售、一般及行政费用：2025年第四季度销售、一般及行政费用为3.08亿美元，较2024年同期下降12%。主要源于多职能领域咨询及外部服务支出缩减，体现公司持续践行成本管控原则。 所得税：由于公司继续对大
Moderna发布2025年财报：全年亏损28亿美元，但2026年增长预期达10%
精彩
BerthaAntoinette:
亏28亿但明年预期10%增长，疫苗获批，等等看数据。
回复
1
点赞
点赞
编组 21备份 2
分享
举报
投阅笔记
·
03-01
美股实盘（28）：-56%到-17.39%
$Figma(FIG)$
$Aurora Innovation(AUR)$
$Tempus AI(TEM)$
$Moderna, Inc.(MRNA)$
$Nu Holdings Ltd.(NU)$
先说下美股实盘文章更新时间为每个月1号，如果1号是周六，那么更新就顺延一天。 本文是美股实盘第二十八篇： 1、收益率 总收益率 如上图所示，目前账户总收益来到了+822.13%，收益率相比上次增长，上次是+789.44%，这是总的账户收益率，接下来看下今年以来的收益率，如下图所示，今年以来的收益率为+3.59%，期间纳斯达克-2.44%，相对收益+6.03%。 接下来说下持仓个股。 2、持仓个股 上次持仓记录： 最新持仓记录： 如上所示目前持仓6个股票,持仓公司相比上次减少1个，清仓公司就是Cloudflare,之后把这些资金全部买入了Aurora，所以该公司持仓相比上次大幅增长：9.48%到20.98%，这次考虑是我认为Aurora主营业务自动驾驶卡车拐点已经到了，股价未来上升空间远远大于Cloudflare。 对了还有其他操作，就是减持Tempus、NU、Modrna，这次资金全部增持Figma，上篇文章说了：如果该公司继续下跌，我会进一步增持。由于我是满仓操作，所以就只能减持其他股票加仓Figma，具体时间是在2月3日，那时候该公司最低跌到20.94,相比我的持仓成本，Figma亏损达到了
美股实盘（28）：-56%到-17.39%
回复
评论
点赞
1
编组 21备份 2
分享
举报
萨姆哥哥
·
02-13
$Moderna, Inc.(MRNA)$
高开低走大概率
$Moderna, Inc.(MRNA)$ 高开低走大概率
回复
评论
点赞
1
编组 21备份 2
分享
举报
直击业绩会
·
02-10
【直播预告】本周财报日历｜直击业绩会(2.9-2.13)
👉 欢迎订阅直播，直击高管解读财报与分析师Q&A 📊 本周财报季重点公司已出炉，本周将转播以下业绩会： 🎯 直播场次：Coinbase｜周五 06:30 📍 直播入口：
Coinbase 2025Q4业绩电话会议
港美股财报季继续！
$中芯国际(00981)$
、华虹半导体、Robinhood、Coinbase、AppLovin等公司放榜 本周，美股传统行业股票例如
$可口可乐(KO)$
、
$T-Mobile US(TMUS)$
、
$英国石油(BP)$
等公司将业绩，医药巨头
$阿斯利康(AZN)$
、
$Moderna(MRNA)$
也将发布财报。 上周市场大跌，投资者将集中关注于近期剧烈波动的AI应用与软件股板块以及关键科技公司，投资者可关注
$Applovin(APP.US)$
和
$Unity Software(U)
【直播预告】本周财报日历｜直击业绩会(2.9-2.13)
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
投阅笔记
·
02-01
美股实盘（27）：亏损继续扩大
$Moderna, Inc.(MRNA)$
$Cloudflare, Inc.(NET)$
$Figma(FIG)$
$Recursion Pharmaceuticals, Inc.(RXRX)$
$Aurora Innovation(AUR)$
先说下美股实盘文章更新时间为每个月1号，如果1号是周六，那么更新就顺延一天。 本文是美股实盘第二十七篇： 1、收益率 总收益率 图片 如上图所示，目前账户总收益来到了+789.44%，收益率相比上次大幅回撤，上次是+860.49%，这是总的账户收益率，接下来看下今年以来的收益率，如下图所示，今年以来的收益率为-0.09%，期间纳斯达克-0.98%，相对收益+0.89%。 图片 接下来说下持仓个股。 2、持仓个股 上次持仓记录： 图片 最新持仓记录： 图片 如上所示目前持仓7个股票,持仓公司相比增加1个，具体公司就是Aurora，这次通过减持Moderna持仓，具体数量是50%的Moderna，然后全部买入Aurora。、 同时可以看到上次增持的Figma继续大幅下跌，持仓亏损继续扩大，从上次的-21.34%到-45.98%，怎么说呢？该公司最初作为基于浏览器的用户界面设计工具诞生，如今Figma的平台已扩展为助力团队实现从创意到产品全流程的一站式解决方案。该公司的产品有助于缩短软件开发时间。Figma首席执行官DylanField说过在人工智能
美股实盘（27）：亏损继续扩大
精彩
Cliff:
亏得肉疼，持仓真磨人！
回复
5
点赞
12
编组 21备份 2
分享
举报
Eric.Hz
·
01-22
$Moderna, Inc.(MRNA)$
$Moderna, Inc.(MRNA)$
回复
评论
点赞
3
编组 21备份 2
分享
举报
我是股神大腿毛
·
01-22
$MRNA 20270115 65.0 CALL$
拿到100
$MRNA 20270115 65.0 CALL$ 拿到100
回复
评论
点赞
2
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
Moderna, Inc.
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.modernatx.com;www.investors.modernatx.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Moderna, Inc.于2016年7月22日根据特拉华州法律注册成立。该公司是信使核糖核酸（信使核糖核酸）医学领域的领导者。通过在科学、技术和健康的交叉领域工作十多年，该公司以前所未有的速度和效率开发出药物，包括最早和最有效的新冠疫苗之一。该公司的mRNA平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗的开发成为可能。凭借独特的文化和由Moderna价值观和思维模式驱动的全球化团队，以负责任的方式改变人类健康的未来，该公司努力通过mRNA药物向人们传递尽可能大的影响。
05-11 12:00
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
05-08
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
05-01
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05-01
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
05-01
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
04-30
超过5%披露
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
03-05
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
03-02
关联方拟减持公告
Form 144 - Report of proposed sale of securities
Form 144 - Report of proposed sale of securities
02-23
关联方拟减持公告
Form 144 | Moderna高管Hoge Stephen拟减持160009股，总价约781.5万美元
Form 144 | Moderna高管Hoge Stephen拟减持160009股，总价约781.5万美元
02-20
员工持股计划
Form S-8 - Securities to be offered to employees in employee benefit plans
Form S-8 - Securities to be offered to employees in employee benefit plans
02-20
年度报告
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
02-13
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
02-11
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-12
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
01-05
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
分时
5日
日
周
月
数据加载中...
最高
54.62
今开
52.24
量比
0.88
最低
51.25
昨收
52.88
换手率
3.10%
热议股票
{"pagemeta":{"title":"Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Moderna, Inc.(MRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Moderna, Inc.,MRNA,Moderna, Inc.股票,Moderna, Inc.股票老虎,Moderna, Inc.股票老虎国际,Moderna, Inc.行情,Moderna, Inc.股票行情,Moderna, Inc.股价,Moderna, Inc.股市,Moderna, Inc.股票价格,Moderna, Inc.股票交易,Moderna, Inc.股票购买,Moderna, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Moderna, Inc.(MRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"MRNA","data":{"stockData":{"symbol":"MRNA","market":"US","secType":"STK","nameCN":"Moderna, Inc.","latestPrice":53.27,"timestamp":1778616000000,"preClose":52.88,"halted":0,"volume":11244991,"hourTrading":{"tag":"盘后","latestPrice":53.27,"preClose":53.27,"latestTime":"19:43 EDT","volume":1595833,"amount":85017104.621021,"timestamp":1778629388633,"change":0,"changeRate":0,"amplitude":0.016707},"delay":0,"changeRate":0.007375189107413021,"floatShares":363290461,"shares":394939400,"eps":-8.14,"marketStatus":"盘后交易","change":0.39,"latestTime":"05-12 19:43:15 EDT","open":52.24,"high":54.62,"low":51.25,"amount":601940241.318303,"amplitude":0.063729,"askPrice":53.76,"askSize":510,"bidPrice":53.27,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-8.14,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778630400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":52.88,"preHourTrading":{"tag":"盘前","latestPrice":52.13,"preClose":52.88,"latestTime":"09:29 EDT","volume":142852,"amount":7639232.1206,"timestamp":1778592599999,"change":-0.75,"changeRate":-0.014183,"amplitude":0.068835},"postHourTrading":{"tag":"盘后","latestPrice":53.27,"preClose":53.27,"latestTime":"19:43 EDT","volume":1595833,"amount":85017104.621021,"timestamp":1778629388633,"change":0,"changeRate":0,"amplitude":0.016707},"volumeRatio":0.877841,"impliedVol":0.8743,"impliedVolPercentile":0.8725},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.560430039614680","cardData":[{"tweetId":"560430039614680","author":{"authorId":"3551233200528073","idStr":"3551233200528073","name":"投阅笔记","avatar":"https://static.tigerbbs.com/880e7458e2b86083ea5fcaee8dd335ea","userType":1,"introduction":"","crmLevel":4,"crmLevelSwitch":1,"wearingBadge":{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.28","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.13","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"wearingBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","redirectLinkValidityFrom":1680048000000,"redirectLinkValidityTo":1996358400000,"validityToTimestamp":1781193648166}],"fanSize":2037,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"Moderna 2026Q1财报：净亏13亿美元，但2026年目标明确——营收增长10%","digest":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 2026年5月1日莫德纳（Moderna）今日公布了2026年第一季度的财务业绩并提供了业务进展更新。 先看下概要： 第一季度营收为3.89亿美元，其中约80%来自国际市场 报告第一季度GAAP净亏损为13亿美元，GAAP每股收益为-3.40美元，其中包括9亿美元的非经常性诉讼和解费用 重申计划在2026年实现最高10%的营收增长及GAAP运营费用削减，该数据不包含非经常性诉讼和解费用 传染病产品组合在欧盟取得关键监管里程碑，包括mNEXSPIKE和mCOMBRIAX（Moderna的流感加新冠联合疫苗）获批 启动III期临床研究，评估intismeran autogene作为单药治疗以及与KEYTRUDA QLEX联合治疗高危I期非小细胞肺癌 Moderna首席执行官Stéphane Bancel表示： “莫德纳团队为今年开了一个好头，在2025年采取的措施基础上，实现了显著的营收增长和大幅的成本削减。我们获得了两项欧洲产品批准，其中包括全球首款流感加新冠联合疫苗mCOMBRIAX。此外，我们还启动了intismeran的新关键性试验——这是针对高危1期非小细胞肺癌患者的首项III期单药治疗研究，依托第一季度的强劲势头，我们很高兴能在2026年重回销售增长轨道，并预期在全球范围内获得多项新批准，其中包括我们的季节性流感疫苗——这将成为莫德纳的第五款获批产品。我们也期待今年在诺如病毒、用于黑色素瘤的intismeran以及丙酸血症项目方面取得重要的关键性试验结果。” 商业动态 第一季度，Moderna通过落实战略合作与关键审批，持续推进其多年期营收增长战略。在英国，公司已根据长期战略合作协议完成了首批产品交付。Moderna还获得了欧洲监管机构对mNE","plainDigest":"$Moderna, Inc.(MRNA)$ 2026年5月1日莫德纳（Moderna）今日公布了2026年第一季度的财务业绩并提供了业务进展更新。 先看下概要： 第一季度营收为3.89亿美元，其中约80%来自国际市场 报告第一季度GAAP净亏损为13亿美元，GAAP每股收益为-3.40美元，其中包括9亿美元的非经常性诉讼和解费用 重申计划在2026年实现最高10%的营收增长及GAAP运营费用削减，该数据不包含非经常性诉讼和解费用 传染病产品组合在欧盟取得关键监管里程碑，包括mNEXSPIKE和mCOMBRIAX（Moderna的流感加新冠联合疫苗）获批 启动III期临床研究，评估intismeran autogene作为单药治疗以及与KEYTRUDA QLEX联合治疗高危I期非小细胞肺癌 Moderna首席执行官Stéphane Bancel表示： “莫德纳团队为今年开了一个好头，在2025年采取的措施基础上，实现了显著的营收增长和大幅的成本削减。我们获得了两项欧洲产品批准，其中包括全球首款流感加新冠联合疫苗mCOMBRIAX。此外，我们还启动了intismeran的新关键性试验——这是针对高危1期非小细胞肺癌患者的首项III期单药治疗研究，依托第一季度的强劲势头，我们很高兴能在2026年重回销售增长轨道，并预期在全球范围内获得多项新批准，其中包括我们的季节性流感疫苗——这将成为莫德纳的第五款获批产品。我们也期待今年在诺如病毒、用于黑色素瘤的intismeran以及丙酸血症项目方面取得重要的关键性试验结果。” 商业动态 第一季度，Moderna通过落实战略合作与关键审批，持续推进其多年期营收增长战略。在英国，公司已根据长期战略合作协议完成了首批产品交付。Moderna还获得了欧洲监管机构对mNE","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1777855444502,"gmtModify":1777971386800,"symbols":["MRNA"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/e181340a882ef304939f98e8062a8708","width":"1280","height":"720"}],"repostCount":0,"viewCount":7692,"likeCount":2,"liked":false,"collected":false,"commentCount":1,"hotComments":[{"id":"560908552914224","author":{"authorId":"9000000000000730","idStr":"9000000000000730","name":"AbnerKeppel","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":8,"introduction":"运营账号","crmLevel":1,"crmLevelSwitch":0,"fanSize":7,"starInvestorFlag":false},"content":"目标还挺明确，但亏这么多还得看看后续表现。","plainContent":"目标还挺明确，但亏这么多还得看看后续表现。","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/560430039614680","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":5944,"displayRows":4,"foldSize":0,"authorId":"3551233200528073"}]},{"cardType":"TWEET","cardId":"TWEET.555926314922200","cardData":[{"tweetId":"555926314922200","author":{"authorId":"4144751444625622","idStr":"4144751444625622","name":"Pan the man","avatar":"https://community-static.tradeup.com/news/2fd53ef58442bc6a50658efeefc5e413","userType":1,"introduction":"","crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":125,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"谁是“制药界的SpaceX”？ 在航天史上，SpaceX之所以颠覆行业，并不在于它设计了更多卫星，而在于它重构了“火箭”这一底层系统，使得发射成本大幅下降、成功率显著提升，并最终成为整个产业链的基础设施。 而在生物医药领域，类似的范式正在发生： 以Moderna、Alnylam Pharmaceuticals为代表的企业，已经证明—— 谁掌握递送技术，谁就掌握了新一代制药工业的“发射权”。 在这一背景下，以AI驱动递送系统设计的平台型公司（如剂泰科技），其战略意义正在被迅速重估： 它们不再只是“做药的公司”，而更像是—— 为整个行业提供“发射能力”的底层系统供应商。 一、最接近“SpaceX”的核心标的（递送=火箭） 1. <a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$ </a> 核心标签：mRNA + LNP递送平台化王者 为什么它是“SpaceX”？ * 核心不是疫苗，而是mRNA + LNP递送系统 * 疫苗只是验证场景，本质是“可编程生物平台” * 类似SpaceX的Falcon 9：一次技术 → 多任务复用 护城河 * 自主LNP体系（摆脱专利依赖） * mRNA设计 + 递送一体化 * 已验证商业化（COVID收入） 投资逻辑 * 正从疫苗公司 → 平台型BioTech * 癌症疫苗、罕见病、心血管都在扩展 * 如果“递送时代”成立，它是最直接受益者 ⸻ 2.<a href=\"https://ttm.financial/S/ALNY\">$阿尔尼拉姆制药公司(ALNY)$ </a> 核心标签：RNAi + 肝脏递送王者 SpaceX属性 * RNAi本身不是难点，递送才是核心壁垒 * 在肝脏递送领域几乎“垄断级优势” 护城河 * GalN","plainDigest":"谁是“制药界的SpaceX”？ 在航天史上，SpaceX之所以颠覆行业，并不在于它设计了更多卫星，而在于它重构了“火箭”这一底层系统，使得发射成本大幅下降、成功率显著提升，并最终成为整个产业链的基础设施。 而在生物医药领域，类似的范式正在发生： 以Moderna、Alnylam Pharmaceuticals为代表的企业，已经证明—— 谁掌握递送技术，谁就掌握了新一代制药工业的“发射权”。 在这一背景下，以AI驱动递送系统设计的平台型公司（如剂泰科技），其战略意义正在被迅速重估： 它们不再只是“做药的公司”，而更像是—— 为整个行业提供“发射能力”的底层系统供应商。 一、最接近“SpaceX”的核心标的（递送=火箭） 1. $Moderna, Inc.(MRNA)$ 核心标签：mRNA + LNP递送平台化王者 为什么它是“SpaceX”？ * 核心不是疫苗，而是mRNA + LNP递送系统 * 疫苗只是验证场景，本质是“可编程生物平台” * 类似SpaceX的Falcon 9：一次技术 → 多任务复用 护城河 * 自主LNP体系（摆脱专利依赖） * mRNA设计 + 递送一体化 * 已验证商业化（COVID收入） 投资逻辑 * 正从疫苗公司 → 平台型BioTech * 癌症疫苗、罕见病、心血管都在扩展 * 如果“递送时代”成立，它是最直接受益者 ⸻ 2.$阿尔尼拉姆制药公司(ALNY)$ 核心标签：RNAi + 肝脏递送王者 SpaceX属性 * RNAi本身不是难点，递送才是核心壁垒 * 在肝脏递送领域几乎“垄断级优势” 护城河 * GalN","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1776757362599,"gmtModify":1776761436107,"symbols":["BEAM","MRNA","ALNY","RXRX","ARCT"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":1586,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/555926314922200","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3007,"displayRows":4,"foldSize":0,"authorId":"4144751444625622"}]},{"cardType":"TWEET","cardId":"TWEET.540760311623968","cardData":[{"tweetId":"540760311623968","author":{"authorId":"36989258284800","idStr":"36989258284800","name":"小虎老师","avatar":"https://static.laohu8.com/6e9d88ae16a2b401169a727cf1457404","userType":8,"introduction":"老虎国际官方账号","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":39269,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"周评：地缘催化美股连跌两周，油价与VIX飙升，美元与债券收益率反弹","digest":"上周回顾 1. 美国市场——地缘政治冲击波驱动避险资金涌入 美国、以色列与伊朗之间的地缘政治紧张局势，以及随之而来的油价飙升，已显著影响市场动态。黄金和白银等避险资产也随之上涨，投资者寻求躲避不确定性。 负面催化剂：受中东冲突、油价上涨以及令人失望的月度就业报告拖累，美股指数连续第二周下跌。 <a href=\"https://laohu8.com/S/.DJI\">$道琼斯(.DJI)$</a> 2.9%， <a href=\"https://laohu8.com/S/.SPX\">$标普500(.SPX)$</a> 回落2.0%， <a href=\"https://laohu8.com/S/.IXIC\">$纳斯达克(.IXIC)$</a> 收跌1.2%。 新兴市场抛售：避险情绪重创国际股市；MSCI EAFE指数和MSCI新兴市场指数均暴跌近7%。 油价飙升：不断升级的军事冲突席卷中东，推动油价升至2023年9月以来最高水平。 VIX跳涨： <a href=\"https://laohu8.com/S/VIX\">$标普500波动率指数(VIX)$</a> 收于29.5，较前一周收盘水平上涨48%。 美元与收益率逆转：周五，10年期美国国债收益率 <a href=\"https://laohu8.com/FUT/ZNmain\">$10年美债主连 2606(ZNmain)$</a> 收于4.15%，高于前一周的3.96%。同时， <a href=\"https://laohu8.com/S/USDindex.FOREX\">$美元指数(USDindex.FOREX)$</a> 在避险资金涌入背景下走强。 四季度财报：根据FactSet数据，标普500指数成分股公司公布的平均盈利较上年同期增长14.0%。 通胀观察：投资者本周关键关注消费者物价指数（周三）和个人消费支出物价指数（周五）或将指","plainDigest":"上周回顾 1. 美国市场——地缘政治冲击波驱动避险资金涌入 美国、以色列与伊朗之间的地缘政治紧张局势，以及随之而来的油价飙升，已显著影响市场动态。黄金和白银等避险资产也随之上涨，投资者寻求躲避不确定性。 负面催化剂：受中东冲突、油价上涨以及令人失望的月度就业报告拖累，美股指数连续第二周下跌。 $道琼斯(.DJI)$ 2.9%， $标普500(.SPX)$ 回落2.0%， $纳斯达克(.IXIC)$ 收跌1.2%。 新兴市场抛售：避险情绪重创国际股市；MSCI EAFE指数和MSCI新兴市场指数均暴跌近7%。 油价飙升：不断升级的军事冲突席卷中东，推动油价升至2023年9月以来最高水平。 VIX跳涨： $标普500波动率指数(VIX)$ 收于29.5，较前一周收盘水平上涨48%。 美元与收益率逆转：周五，10年期美国国债收益率 $10年美债主连 2606(ZNmain)$ 收于4.15%，高于前一周的3.96%。同时， $美元指数(USDindex.FOREX)$ 在避险资金涌入背景下走强。 四季度财报：根据FactSet数据，标普500指数成分股公司公布的平均盈利较上年同期增长14.0%。 通胀观察：投资者本周关键关注消费者物价指数（周三）和个人消费支出物价指数（周五）或将指","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1773047639249,"gmtModify":1773047716480,"symbols":["CRWD","AAOI","PLUG","02015","06618","ORCL","EB5.SI","NIO","MRNA","LEN","RIO","BBAI","LI","MRVL",".DJI","DG","VIX","XJO.AU","00100","COIN","CIEN","BS6.SI","MSFT","BILI","HSI","USDindex.FOREX","WDS","CRDO","F34.SI","AEM","TSM","02318","ASTS","09626","09866","INTC","C52.SI","ACHR","HSTECH","STO.AU","V03.SI","JD",".SPX","C6L.SI","ADBE","HPE","S63.SI","AVGO","TTD","BRK.B","BHP","CBA.AU","09618","02866","02228","01138","SE","9CI.SI","COST","STI.SI",".IXIC","NAB.AU","ZNmain","PNGAY","601318","601866","600026"],"themeIds":["fb0b8a84b3ed43f49e4a9bb328a89463","c7beb8c494764725b3b94f2f414bb12c","e4363384c4254650b897c0f13fe1588f","cc65bfe8ff7145cf8db4716572f98414"],"popularizeThemeFlag":false,"imageCount":3,"images":[{"url":"https://static.tigerbbs.com/7ac4780b7b3af7486696f6770ba545b2"},{"url":"https://static.tigerbbs.com/f06cf01e6fc1e5a229c86d044c239346"},{"url":"https://static.tigerbbs.com/7cad0a6f374fd59e2de09738facab3a7"}],"repostCount":0,"viewCount":22250,"likeCount":11,"liked":false,"collected":false,"commentCount":1,"hotComments":[{"id":"546121642980384","author":{"authorId":"3468814734547554","idStr":"3468814734547554","name":"Sige heil","avatar":"https://static.tigerbbs.com/62c6cab60c1c4a1564347905ed91acb4","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"fanSize":3,"starInvestorFlag":false},"content":"什么意思。美股要涨 大a又…","plainContent":"什么意思。美股要涨 大a又…","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/540760311623968","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":true,"upFlag":false,"length":7081,"displayRows":4,"foldSize":0,"authorId":"36989258284800"}]},{"cardType":"TWEET","cardId":"TWEET.539227554152496","cardData":[{"tweetId":"539227554152496","author":{"authorId":"3551233200528073","idStr":"3551233200528073","name":"投阅笔记","avatar":"https://static.tigerbbs.com/880e7458e2b86083ea5fcaee8dd335ea","userType":1,"introduction":"","crmLevel":4,"crmLevelSwitch":1,"wearingBadge":{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.28","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.13","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"wearingBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","redirectLinkValidityFrom":1680048000000,"redirectLinkValidityTo":1996358400000,"validityToTimestamp":1781193648166}],"fanSize":2037,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"Moderna发布2025年财报：全年亏损28亿美元，但2026年增长预期达10%","digest":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> 2026年2月13日Moderna公布2025年第四季度财务业绩及业务进展。 业绩概要： 第四季度营收7亿美元，公认会计准则净亏损8亿美元，每股收益亏损2.11美元 全年营收19亿美元，公认会计准则净亏损28亿美元，公认会计准则摊薄每股收益亏损7.26美元 重申2026年营收增长目标达10%，并计划削减GAAP运营支出 宣布流感疫苗获欧盟、加拿大及澳大利亚监管机构受理；美国FDA发出拒收函，公司已申请A类会议商讨后续路径(最新消息已经通过) 诺如病毒三期临床试验完成患者招募，数据读出预计于2026年完成 宣布肌层浸润性膀胱癌II期intismeran自体移植试验完成患者招募 2025年第四季度财务业绩 收入：2025年第四季度总收入达6.78亿美元，处于公司前期预期区间上限，主要由新冠疫苗销售驱动。其中美国市场产品销售额为2.64亿美元，国际市场为3.81亿美元。与2024年同期相比，第四季度收入下降30%，主要反映新冠疫苗销量较上年同期减少。 销售成本：2025年第四季度销售成本为4.52亿美元，包含第三方特许权使用费3400万美元及库存减值1.44亿美元。销售成本较2024年同期下降39%，主要反映合同制造业务收尾成本及库存减值减少。 研发费用：2025年第四季度研发费用为7.75亿美元，较2024年同期下降31%。主要因临床开发及生产成本降低所致，反映出大型III期呼吸系统项目逐步收尾、持续推进产品组合优先级调整以及全公司范围内的成本管控成效。 销售、一般及行政费用：2025年第四季度销售、一般及行政费用为3.08亿美元，较2024年同期下降12%。主要源于多职能领域咨询及外部服务支出缩减，体现公司持续践行成本管控原则。 所得税：由于公司继续对大","plainDigest":"$Moderna, Inc.(MRNA)$ 2026年2月13日Moderna公布2025年第四季度财务业绩及业务进展。 业绩概要： 第四季度营收7亿美元，公认会计准则净亏损8亿美元，每股收益亏损2.11美元 全年营收19亿美元，公认会计准则净亏损28亿美元，公认会计准则摊薄每股收益亏损7.26美元 重申2026年营收增长目标达10%，并计划削减GAAP运营支出 宣布流感疫苗获欧盟、加拿大及澳大利亚监管机构受理；美国FDA发出拒收函，公司已申请A类会议商讨后续路径(最新消息已经通过) 诺如病毒三期临床试验完成患者招募，数据读出预计于2026年完成 宣布肌层浸润性膀胱癌II期intismeran自体移植试验完成患者招募 2025年第四季度财务业绩 收入：2025年第四季度总收入达6.78亿美元，处于公司前期预期区间上限，主要由新冠疫苗销售驱动。其中美国市场产品销售额为2.64亿美元，国际市场为3.81亿美元。与2024年同期相比，第四季度收入下降30%，主要反映新冠疫苗销量较上年同期减少。 销售成本：2025年第四季度销售成本为4.52亿美元，包含第三方特许权使用费3400万美元及库存减值1.44亿美元。销售成本较2024年同期下降39%，主要反映合同制造业务收尾成本及库存减值减少。 研发费用：2025年第四季度研发费用为7.75亿美元，较2024年同期下降31%。主要因临床开发及生产成本降低所致，反映出大型III期呼吸系统项目逐步收尾、持续推进产品组合优先级调整以及全公司范围内的成本管控成效。 销售、一般及行政费用：2025年第四季度销售、一般及行政费用为3.08亿美元，较2024年同期下降12%。主要源于多职能领域咨询及外部服务支出缩减，体现公司持续践行成本管控原则。 所得税：由于公司继续对大","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772668321079,"gmtModify":1772674629491,"symbols":["MRNA"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/e181340a882ef304939f98e8062a8708","width":"1280","height":"720"}],"repostCount":0,"viewCount":2669,"likeCount":0,"liked":false,"collected":false,"commentCount":1,"hotComments":[{"id":"539269723616952","author":{"authorId":"9000000000000683","idStr":"9000000000000683","name":"BerthaAntoinette","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":8,"introduction":"运营账号","crmLevel":1,"crmLevelSwitch":0,"fanSize":0,"starInvestorFlag":false},"content":"亏28亿但明年预期10%增长，疫苗获批，等等看数据。","plainContent":"亏28亿但明年预期10%增长，疫苗获批，等等看数据。","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/539227554152496","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":5803,"displayRows":4,"foldSize":0,"authorId":"3551233200528073"}]},{"cardType":"TWEET","cardId":"TWEET.537867839963976","cardData":[{"tweetId":"537867839963976","author":{"authorId":"3551233200528073","idStr":"3551233200528073","name":"投阅笔记","avatar":"https://static.tigerbbs.com/880e7458e2b86083ea5fcaee8dd335ea","userType":1,"introduction":"","crmLevel":4,"crmLevelSwitch":1,"wearingBadge":{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.28","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.13","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"wearingBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","redirectLinkValidityFrom":1680048000000,"redirectLinkValidityTo":1996358400000,"validityToTimestamp":1781193648166}],"fanSize":2037,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"美股实盘（28）：-56%到-17.39%","digest":"<a href=\"https://laohu8.com/S/FIG\">$Figma(FIG)$</a> <a href=\"https://laohu8.com/S/AUR\">$Aurora Innovation(AUR)$</a> <a href=\"https://laohu8.com/S/TEM\">$Tempus AI(TEM)$</a> <a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> <a href=\"https://laohu8.com/S/NU\">$Nu Holdings Ltd.(NU)$</a> 先说下美股实盘文章更新时间为每个月1号，如果1号是周六，那么更新就顺延一天。 本文是美股实盘第二十八篇： 1、收益率 总收益率 如上图所示，目前账户总收益来到了+822.13%，收益率相比上次增长，上次是+789.44%，这是总的账户收益率，接下来看下今年以来的收益率，如下图所示，今年以来的收益率为+3.59%，期间纳斯达克-2.44%，相对收益+6.03%。 接下来说下持仓个股。 2、持仓个股 上次持仓记录： 最新持仓记录： 如上所示目前持仓6个股票,持仓公司相比上次减少1个，清仓公司就是Cloudflare,之后把这些资金全部买入了Aurora，所以该公司持仓相比上次大幅增长：9.48%到20.98%，这次考虑是我认为Aurora主营业务自动驾驶卡车拐点已经到了，股价未来上升空间远远大于Cloudflare。 对了还有其他操作，就是减持Tempus、NU、Modrna，这次资金全部增持Figma，上篇文章说了：如果该公司继续下跌，我会进一步增持。由于我是满仓操作，所以就只能减持其他股票加仓Figma，具体时间是在2月3日，那时候该公司最低跌到20.94,相比我的持仓成本，Figma亏损达到了","plainDigest":"$Figma(FIG)$ $Aurora Innovation(AUR)$ $Tempus AI(TEM)$ $Moderna, Inc.(MRNA)$ $Nu Holdings Ltd.(NU)$ 先说下美股实盘文章更新时间为每个月1号，如果1号是周六，那么更新就顺延一天。 本文是美股实盘第二十八篇： 1、收益率 总收益率 如上图所示，目前账户总收益来到了+822.13%，收益率相比上次增长，上次是+789.44%，这是总的账户收益率，接下来看下今年以来的收益率，如下图所示，今年以来的收益率为+3.59%，期间纳斯达克-2.44%，相对收益+6.03%。 接下来说下持仓个股。 2、持仓个股 上次持仓记录： 最新持仓记录： 如上所示目前持仓6个股票,持仓公司相比上次减少1个，清仓公司就是Cloudflare,之后把这些资金全部买入了Aurora，所以该公司持仓相比上次大幅增长：9.48%到20.98%，这次考虑是我认为Aurora主营业务自动驾驶卡车拐点已经到了，股价未来上升空间远远大于Cloudflare。 对了还有其他操作，就是减持Tempus、NU、Modrna，这次资金全部增持Figma，上篇文章说了：如果该公司继续下跌，我会进一步增持。由于我是满仓操作，所以就只能减持其他股票加仓Figma，具体时间是在2月3日，那时候该公司最低跌到20.94,相比我的持仓成本，Figma亏损达到了","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1772336275964,"gmtModify":1772341506551,"symbols":["FIG","TEM","MRNA","AUR","NU"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":6,"images":[{"url":"https://static.tigerbbs.com/e181340a882ef304939f98e8062a8708","width":"1280","height":"720"}],"repostCount":0,"viewCount":2948,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/537867839963976","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":11559,"displayRows":4,"foldSize":0,"authorId":"3551233200528073"}]},{"cardType":"TWEET","cardId":"TWEET.532365592597544","cardData":[{"tweetId":"532365592597544","author":{"authorId":"3548294102254426","idStr":"3548294102254426","name":"萨姆哥哥","avatar":"https://static.tigerbbs.com/788a9bf830209fbeebdc48bca7fd8c75","userType":1,"introduction":"","crmLevel":7,"crmLevelSwitch":1,"wearingBadge":{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.12","exceedPercentage":"93.49%","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":3,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$ </a> 高开低走大概率","plainDigest":"$Moderna, Inc.(MRNA)$ 高开低走大概率","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770992956085,"gmtModify":1770992958271,"symbols":["MRNA"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":1302,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/532365592597544","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":34,"displayRows":4,"foldSize":0,"authorId":"3548294102254426"}]},{"cardType":"TWEET","cardId":"TWEET.531120403443752","cardData":[{"tweetId":"531120403443752","author":{"authorId":"3515627051568386","idStr":"3515627051568386","name":"直击业绩会","avatar":"https://static.tigerbbs.com/6cc211c0c1b0a527888a896b6b9b0e33","userType":4,"introduction":"聚焦美港股财报业绩会，搬运业绩会中文字稿/视频","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":6536,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"【直播预告】本周财报日历｜直击业绩会(2.9-2.13)","digest":"👉 欢迎订阅直播，直击高管解读财报与分析师Q&A 📊 本周财报季重点公司已出炉，本周将转播以下业绩会： 🎯 直播场次：Coinbase｜周五 06:30 📍 直播入口：<a href=\"https://laohu8.com/RN?name=RNLive&rndata=%7B%22liveId%22:%221856121037545803%22,%22type%22:2%7D\" target=\"_blank\">Coinbase 2025Q4业绩电话会议</a> 港美股财报季继续！<a href=\"https://laohu8.com/S/00981\">$中芯国际(00981)$</a>、华虹半导体、Robinhood、Coinbase、AppLovin等公司放榜 本周，美股传统行业股票例如<a href=\"https://laohu8.com/S/KO\">$可口可乐(KO)$</a>、<a href=\"https://laohu8.com/S/TMUS\">$T-Mobile US(TMUS)$</a>、<a href=\"https://laohu8.com/S/BP\">$英国石油(BP)$</a>等公司将业绩，医药巨头<a href=\"https://laohu8.com/S/AZN\">$阿斯利康(AZN)$</a> 、 <a href=\"https://laohu8.com/S/MRNA\">$Moderna(MRNA)$</a>也将发布财报。 上周市场大跌，投资者将集中关注于近期剧烈波动的AI应用与软件股板块以及关键科技公司，投资者可关注<a href=\"https://laohu8.com/S/APP.US\">$Applovin(APP.US)$</a>和<a href=\"https://laohu8.com/S/U\">$Unity Software(U)</a>","plainDigest":"👉 欢迎订阅直播，直击高管解读财报与分析师Q&A 📊 本周财报季重点公司已出炉，本周将转播以下业绩会： 🎯 直播场次：Coinbase｜周五 06:30 📍 直播入口：Coinbase 2025Q4业绩电话会议 港美股财报季继续！$中芯国际(00981)$、华虹半导体、Robinhood、Coinbase、AppLovin等公司放榜 本周，美股传统行业股票例如$可口可乐(KO)$、$T-Mobile US(TMUS)$、$英国石油(BP)$等公司将业绩，医药巨头$阿斯利康(AZN)$ 、 $Moderna(MRNA)$也将发布财报。 上周市场大跌，投资者将集中关注于近期剧烈波动的AI应用与软件股板块以及关键科技公司，投资者可关注$Applovin(APP.US)$和$Unity Software(U)","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770688402525,"gmtModify":1770688801545,"symbols":["KO","F","RIVN","00981","BP","COIN","01347","09999","TMUS","MRNA","AZN","U","HOOD","APP.US","688347","688981","NTES"],"themeIds":["e9fb75eed70244c7bb7cc18e8cbc862e"],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/63d1423fd98b97bd8165369c1ba38866"}],"repostCount":0,"viewCount":14380,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/531120403443752","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":true,"upFlag":false,"length":762,"displayRows":4,"foldSize":0,"authorId":"3515627051568386"}]},{"cardType":"TWEET","cardId":"TWEET.527943299048280","cardData":[{"tweetId":"527943299048280","author":{"authorId":"3551233200528073","idStr":"3551233200528073","name":"投阅笔记","avatar":"https://static.tigerbbs.com/880e7458e2b86083ea5fcaee8dd335ea","userType":1,"introduction":"","crmLevel":4,"crmLevelSwitch":1,"wearingBadge":{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.28","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.13","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":1}],"wearingBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","redirectLinkValidityFrom":1680048000000,"redirectLinkValidityTo":1996358400000,"validityToTimestamp":1781193648166}],"fanSize":2037,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"美股实盘（27）：亏损继续扩大","digest":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a> <a href=\"https://laohu8.com/S/NET\">$Cloudflare, Inc.(NET)$</a> <a href=\"https://laohu8.com/S/FIG\">$Figma(FIG)$</a> <a href=\"https://laohu8.com/S/RXRX\">$Recursion Pharmaceuticals, Inc.(RXRX)$</a> <a href=\"https://laohu8.com/S/AUR\">$Aurora Innovation(AUR)$</a> 先说下美股实盘文章更新时间为每个月1号，如果1号是周六，那么更新就顺延一天。 本文是美股实盘第二十七篇： 1、收益率 总收益率 图片 如上图所示，目前账户总收益来到了+789.44%，收益率相比上次大幅回撤，上次是+860.49%，这是总的账户收益率，接下来看下今年以来的收益率，如下图所示，今年以来的收益率为-0.09%，期间纳斯达克-0.98%，相对收益+0.89%。 图片 接下来说下持仓个股。 2、持仓个股 上次持仓记录： 图片 最新持仓记录： 图片 如上所示目前持仓7个股票,持仓公司相比增加1个，具体公司就是Aurora，这次通过减持Moderna持仓，具体数量是50%的Moderna，然后全部买入Aurora。、 同时可以看到上次增持的Figma继续大幅下跌，持仓亏损继续扩大，从上次的-21.34%到-45.98%，怎么说呢？该公司最初作为基于浏览器的用户界面设计工具诞生，如今Figma的平台已扩展为助力团队实现从创意到产品全流程的一站式解决方案。该公司的产品有助于缩短软件开发时间。Figma首席执行官DylanField说过在人工智能","plainDigest":"$Moderna, Inc.(MRNA)$ $Cloudflare, Inc.(NET)$ $Figma(FIG)$ $Recursion Pharmaceuticals, Inc.(RXRX)$ $Aurora Innovation(AUR)$ 先说下美股实盘文章更新时间为每个月1号，如果1号是周六，那么更新就顺延一天。 本文是美股实盘第二十七篇： 1、收益率 总收益率 图片 如上图所示，目前账户总收益来到了+789.44%，收益率相比上次大幅回撤，上次是+860.49%，这是总的账户收益率，接下来看下今年以来的收益率，如下图所示，今年以来的收益率为-0.09%，期间纳斯达克-0.98%，相对收益+0.89%。 图片 接下来说下持仓个股。 2、持仓个股 上次持仓记录： 图片 最新持仓记录： 图片 如上所示目前持仓7个股票,持仓公司相比增加1个，具体公司就是Aurora，这次通过减持Moderna持仓，具体数量是50%的Moderna，然后全部买入Aurora。、 同时可以看到上次增持的Figma继续大幅下跌，持仓亏损继续扩大，从上次的-21.34%到-45.98%，怎么说呢？该公司最初作为基于浏览器的用户界面设计工具诞生，如今Figma的平台已扩展为助力团队实现从创意到产品全流程的一站式解决方案。该公司的产品有助于缩短软件开发时间。Figma首席执行官DylanField说过在人工智能","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769913302467,"gmtModify":1769913464545,"symbols":["FIG","MRNA","RXRX","NET","AUR"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":5,"images":[{"url":"https://static.tigerbbs.com/e181340a882ef304939f98e8062a8708","width":"1280","height":"720"}],"repostCount":0,"viewCount":19853,"likeCount":12,"liked":false,"collected":false,"commentCount":5,"hotComments":[{"id":"527952076575800","author":{"authorId":"9000000000000649","idStr":"9000000000000649","name":"Cliff","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":8,"introduction":"运营账号","crmLevel":1,"crmLevelSwitch":0,"fanSize":0,"starInvestorFlag":false},"content":"亏得肉疼，持仓真磨人！","plainContent":"亏得肉疼，持仓真磨人！","likeCount":0,"commentType":"hot","coins":0},{"id":"527958118044520","author":{"authorId":"4087422624240810","idStr":"4087422624240810","name":"AliceSam","avatar":"https://static.tigerbbs.com/77ff717dd7a06de56315c65060829a03","userType":1,"introduction":"","crmLevel":5,"crmLevelSwitch":0,"fanSize":4612,"starInvestorFlag":true,"starInvestorFollowerNum":457},"content":"定期公开实盘的，都是勇士，佩服 [强]","plainContent":"定期公开实盘的，都是勇士，佩服 [强]","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":true,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/527943299048280","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":5648,"displayRows":4,"foldSize":0,"authorId":"3551233200528073"}]},{"cardType":"TWEET","cardId":"TWEET.524780804289048","cardData":[{"tweetId":"524780804289048","author":{"authorId":"4203488005337362","idStr":"4203488005337362","name":"Eric.Hz","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.09","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","name":"实盘交易者","description":"完成一笔实盘交易","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$ </a> ","plainDigest":"$Moderna, Inc.(MRNA)$","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769096430698,"gmtModify":1769098725851,"symbols":["MRNA"],"themeIds":["5bfad02ab61749c8bfe6573ac7bbe8a3"],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/7eef895632e66cb0e247a92412e823e2","width":"927","height":"1599"}],"repostCount":0,"viewCount":1270,"likeCount":3,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/524780804289048","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"upFlag":false,"length":20,"displayRows":4,"foldSize":0,"authorId":"4203488005337362"}]},{"cardType":"TWEET","cardId":"TWEET.524790835347800","cardData":[{"tweetId":"524790835347800","author":{"authorId":"320642945183470","idStr":"320642945183470","name":"我是股神大腿毛","avatar":"https://static.laohu8.com/279c4665f3b5baf86875c8fd7c8b4a20","userType":1,"introduction":"","userGiftHeadFrame":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":8,"crmLevelSwitch":1,"wearingBadge":{"badgeId":"d5d1b81d9a9a4306a42a1560851c3454-5","templateUuid":"d5d1b81d9a9a4306a42a1560851c3454","name":"Live trading challenger","description":"for 10 months","bigImgUrl":"https://static.tigerbbs.com/de3f2938b1f9dddd923333ef958535f5","smallImgUrl":"https://static.tigerbbs.com/a6b8bf4481e36ae8a863eae5098461e6","grayImgUrl":"https://static.tigerbbs.com/91c1c1e4d3607b46e414ab97cc6dd982","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.03","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"wearingBadges":[{"badgeId":"d5d1b81d9a9a4306a42a1560851c3454-5","name":"实盘挑战","description":"累计达10个月","smallImgUrl":"https://static.tigerbbs.com/a6b8bf4481e36ae8a863eae5098461e6","bigImgUrl":"https://static.tigerbbs.com/de3f2938b1f9dddd923333ef958535f5","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":1701388800000,"redirectLinkValidityTo":1725062400000},{"badgeId":"35ec162348d5460f88c959321e554969-3","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000},{"badgeId":"10d8ad8d391644a888f8cb7af2d056a4-1","name":"2025元宝x1","description":"2025年度投资收益达成10万美金","smallImgUrl":"https://static.tigerbbs.com/77da5fe9da608523f0fd7cf355adc306","bigImgUrl":"https://static.tigerbbs.com/77da5fe9da608523f0fd7cf355adc306","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":1171,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/OPT/MRNA 20270115 65.0 CALL\">$MRNA 20270115 65.0 CALL$</a> 拿到100","plainDigest":"$MRNA 20270115 65.0 CALL$ 拿到100","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1769094152224,"gmtModify":1769094164333,"symbols":["MRNA","MRNA 20270115 65.0 CALL"],"themeIds":["5bfad02ab61749c8bfe6573ac7bbe8a3"],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/e2d252e1d520bfa2ae78326f5e763fdc","width":"1122","height":"1737"}],"repostCount":0,"viewCount":2061,"likeCount":2,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/524790835347800","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"upFlag":false,"length":29,"displayRows":4,"foldSize":0,"authorId":"320642945183470"}]}],"size":10},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"21237723","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000101-MRNA","pdf_url":"","pub_time":1778472000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"MRNA","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/0001682852-26-000101-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year;\nItem 5.07: Submission of Matters to a Vote of Security Holders;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-3.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/by-lawamendment5626.htm","primary":true,"translateUrl":"","linkName":"by-lawamendment5626.htm","type":"EX-3.1","id":"NTFILEGiyughgToPoYGvVi","market":"us","size":4452},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000101/mrna-20260506.htm","primary":false,"translateUrl":"","linkName":"mrna-20260506.htm","type":"8-K","id":"NTFILEE9SxgpnaTmBUCsSJ","market":"us","size":48455}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-05-11 12:00","pubTimestamp":1778472000,"title_zh":"Form 8-K - Current report","summary_en":"Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year;\nItem 5.07: Submission of Matters to a Vote of Security Holders;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第5.03项：公司章程或章程的修订；财政年度的变化；项目5.07：将事项提交证券持有人表决；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21232549","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326003415-MRNA","pdf_url":"","pub_time":1778212800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"MRNA","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000195917326003415/0001959173-26-003415-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1035440/000195917326003415/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEAxTEUMyitF4xsa5x","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-05-08 12:00","pubTimestamp":1778212800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21202962","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000060-MRNA","pdf_url":"","pub_time":1777608000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"MRNA","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/0001682852-26-000060-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331.htm","primary":true,"translateUrl":"","linkName":"mrna-20260331.htm","type":"10-Q","id":"NTFILE38xturTYopvv9Ld7","market":"us","size":1195425},{"description":"EX-10.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/exhibit10133126.htm","primary":false,"translateUrl":"","linkName":"exhibit10133126.htm","type":"EX-10.1","id":"NTFILEAJEgGMyJVhgURDyN","market":"us","size":197741},{"description":"EX-31.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/exhibit31133126.htm","primary":false,"translateUrl":"","linkName":"exhibit31133126.htm","type":"EX-31.1","id":"NTFILEAsjxrjorh3Yn4Bj7","market":"us","size":9042},{"description":"EX-31.2","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/exhibit31233126.htm","primary":false,"translateUrl":"","linkName":"exhibit31233126.htm","type":"EX-31.2","id":"NTFILE2FTaCRBKv14KjTqe","market":"us","size":8982},{"description":"EX-32.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/exhibit32133126.htm","primary":false,"translateUrl":"","linkName":"exhibit32133126.htm","type":"EX-32.1","id":"NTFILE9NmqGjm4ZQn2K7Vh","market":"us","size":8107},{"description":"","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331_g1.jpg","primary":false,"translateUrl":"","linkName":"mrna-20260331_g1.jpg","type":"GRAPHIC","id":"NTFILE6frWcXxytLBgjNaS","market":"us","size":63925},{"description":"","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331_g2.jpg","primary":false,"translateUrl":"","linkName":"mrna-20260331_g2.jpg","type":"GRAPHIC","id":"NTFILEFYLZL8HBP72CR2L7","market":"us","size":165976}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2026-05-01 12:00","pubTimestamp":1777608000,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21200466","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326003168-MRNA","pdf_url":"","pub_time":1777608000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"MRNA","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000195917326003168/0001959173-26-003168-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000195917326003168/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE5YWtrbajxWAwuqTM","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-05-01 12:00","pubTimestamp":1777608000,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21200459","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000057-MRNA","pdf_url":"","pub_time":1777608000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"MRNA","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/0001682852-26-000057-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/exhibit9912026q1pressrelea.htm","primary":true,"translateUrl":"","linkName":"exhibit9912026q1pressrelea.htm","type":"EX-99.1","id":"NTFILE2hkM5c8vsbaD7x7y","market":"us","size":144591},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/mrna-20260501.htm","primary":false,"translateUrl":"","linkName":"mrna-20260501.htm","type":"8-K","id":"NTFILE8A2druyK6WT7YakB","market":"us","size":29843}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-05-01 12:00","pubTimestamp":1777608000,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21197400","market":"us","labels":[],"media":"sec.gov","original_id":"AN210011926000785-MRNA","pdf_url":"","pub_time":1777521600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","symbol":"MRNA","title":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000210011926000785/0002100119-26-000785-index.htm","us_notice_code":"Form SCHEDULE 13G","us_title_en":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000210011926000785/xslSCHEDULE_13G_X02/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"SCHEDULE 13G","id":"NTFILEEtAX8sMu29QLUiUY","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2026-04-30 12:00","pubTimestamp":1777521600,"title_zh":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20806084","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000047-MRNA","pdf_url":"","pub_time":1772673641000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"MRNA","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/0001682852-26-000047-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"8-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/mrna-20260303.htm","primary":true,"translateUrl":"","linkName":"mrna-20260303.htm","type":"8-K","id":"NTFILEEJQjzxBLz6iSscSw","market":"us","size":36104}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-03-05 09:20","pubTimestamp":1772673641,"title_zh":"Form 8-K - Current report","summary_en":"Item 1.01: Entry into a Material Definitive Agreement","summary_zh":"项目1.01：订立重大最终协议","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20784451","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326001610-MRNA","pdf_url":"","pub_time":1772427600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"MRNA","title":"Form 144 - Report of proposed sale of securities","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000195917326001610/0001959173-26-001610-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000195917326001610/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILE5Eos9adRKb78CrHy","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-03-02 13:00","pubTimestamp":1772427600,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20755926","market":"us","labels":[],"media":"sec.gov","original_id":"AN195917326001320-MRNA","pdf_url":"","pub_time":1771822800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 144 - Report of proposed sale of securities","symbol":"MRNA","title":"Form 144 | Moderna高管Hoge Stephen拟减持160009股，总价约781.5万美元","titleType":"关联方拟减持公告","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000195917326001320/0001959173-26-001320-index.htm","us_notice_code":"Form 144","us_title_en":"Form 144 - Report of proposed sale of securities","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"Form 144 | Moderna高管Hoge Stephen拟减持160009股，总价约781.5万美元","gpt_en_title":"Form 144 | Moderna's Officer Hoge Stephen proposes to sell 160,009 Shares, with a total value of approximately $7.81 Million.","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000195917326001320/xsl144X01/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"144","id":"NTFILEEaQeaC9o8JxnP6un","market":"us","size":0}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Proposed Sale Of Securities","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"关联方拟减持公告","pubTime":"2026-02-23 13:00","pubTimestamp":1771822800,"title_zh":"Form 144 - Report of proposed sale of securities","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","is_gpt_notice":1,"gpt_icon":1},{"cdn_pdf":false,"hasAttachments":true,"id":"20753184","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000034-MRNA","pdf_url":"","pub_time":1771563600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-8 - Securities to be offered to employees in employee benefit plans","symbol":"MRNA","title":"Form S-8 - Securities to be offered to employees in employee benefit plans","titleType":"员工持股计划","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000034/0001682852-26-000034-index.htm","us_notice_code":"Form S-8","us_title_en":"Form S-8 - Securities to be offered to employees in employee benefit plans","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"S-8","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000034/modernaforms-8feb2026.htm","primary":true,"translateUrl":"","linkName":"modernaforms-8feb2026.htm","type":"S-8","id":"NTFILE7LEPwbwDs6hcQNww","market":"us","size":47959},{"description":"","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000034/exfilingfees022026.htm","primary":false,"translateUrl":"","linkName":"exfilingfees022026.htm","type":"EX-FILING FEES","id":"NTFILEFw34btnarpWmMBLB","market":"us","size":17098},{"description":"EX-5.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000034/exhibit51opinionfors-8gp22.htm","primary":false,"translateUrl":"","linkName":"exhibit51opinionfors-8gp22.htm","type":"EX-5.1","id":"NTFILEEpLjotxgLvCujHbe","market":"us","size":8663},{"description":"EX-23.1","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000034/exhibit231eys-8consent22026.htm","primary":false,"translateUrl":"","linkName":"exhibit231eys-8consent22026.htm","type":"EX-23.1","id":"NTFILEE6TBk15ec7jF7cek","market":"us","size":2707},{"description":"","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000034/image_0.jpg","primary":false,"translateUrl":"","linkName":"image_0.jpg","type":"GRAPHIC","id":"NTFILE96gYyL3DPFaQe2Kk","market":"us","size":13323}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Employee Stock Ownership","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"员工持股计划","pubTime":"2026-02-20 13:00","pubTimestamp":1771563600,"title_zh":"Form S-8 - Securities to be offered to employees in employee benefit plans","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20753141","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000033-MRNA","pdf_url":"","pub_time":1771563600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","symbol":"MRNA","title":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","titleType":"年度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/0001682852-26-000033-index.htm","us_notice_code":"Form 10-K","us_title_en":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm","primary":true,"translateUrl":"","linkName":"mrna-20251231.htm","type":"10-K","id":"NTFILECQyUkgqA5BzEL28K","market":"us","size":2677412},{"description":"EX-4.2","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/exhibit4212312025.htm","primary":false,"translateUrl":"","linkName":"exhibit4212312025.htm","type":"EX-4.2","id":"NTFILE4yCNGf3WRHt4Z8n5","market":"us","size":20605},{"description":"EX-10.16","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/exhibit1016esppplan.htm","primary":false,"translateUrl":"","linkName":"exhibit1016esppplan.htm","type":"EX-10.16","id":"NTFILEFjhP7uhaFpdiLWKJ","market":"us","size":46160},{"description":"EX-19","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/exhibit19insidertradingpol.htm","primary":false,"translateUrl":"","linkName":"exhibit19insidertradingpol.htm","type":"EX-19","id":"NTFILE5yQcNYJKwUQjRALo","market":"us","size":43077},{"description":"EX-21.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/exhibit211subsidiaries1231.htm","primary":false,"translateUrl":"","linkName":"exhibit211subsidiaries1231.htm","type":"EX-21.1","id":"NTFILEEBz3oy58pPSj9B2Q","market":"us","size":16869},{"description":"EX-23.1","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/exhibit23112312025.htm","primary":false,"translateUrl":"","linkName":"exhibit23112312025.htm","type":"EX-23.1","id":"NTFILE9oSCeqLK5QSESZvT","market":"us","size":5458},{"description":"EX-31.1","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/exhibit31112312025.htm","primary":false,"translateUrl":"","linkName":"exhibit31112312025.htm","type":"EX-31.1","id":"NTFILE4rPWJZVPRbsf8ur3","market":"us","size":9455},{"description":"EX-31.2","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/exhibit31212312025.htm","primary":false,"translateUrl":"","linkName":"exhibit31212312025.htm","type":"EX-31.2","id":"NTFILEF1QPA7WayrmRG7sY","market":"us","size":9136},{"description":"EX-32.1","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/exhibit32112312025.htm","primary":false,"translateUrl":"","linkName":"exhibit32112312025.htm","type":"EX-32.1","id":"NTFILE8UHm1C4BLHcZuuBy","market":"us","size":6484},{"description":"EX-32.2","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/exhibit32212312025.htm","primary":false,"translateUrl":"","linkName":"exhibit32212312025.htm","type":"EX-32.2","id":"NTFILE4EZkEnLCiXK5Uprj","market":"us","size":6472},{"description":"","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/image_0.jpg","primary":false,"translateUrl":"","linkName":"image_0.jpg","type":"GRAPHIC","id":"NTFILEEAEpEch3519K8bhS","market":"us","size":21831},{"description":"","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231_g1.jpg","primary":false,"translateUrl":"","linkName":"mrna-20251231_g1.jpg","type":"GRAPHIC","id":"NTFILE8iV29LB5AYvX7t4z","market":"us","size":63925},{"description":"","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231_g2.jpg","primary":false,"translateUrl":"","linkName":"mrna-20251231_g2.jpg","type":"GRAPHIC","id":"NTFILE3BdgKkjRJayaMW4W","market":"us","size":54660},{"description":"","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231_g3.jpg","primary":false,"translateUrl":"","linkName":"mrna-20251231_g3.jpg","type":"GRAPHIC","id":"NTFILEGHfxn7fxgj2h7MtJ","market":"us","size":120464},{"description":"","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231_g4.jpg","primary":false,"translateUrl":"","linkName":"mrna-20251231_g4.jpg","type":"GRAPHIC","id":"NTFILEGVBvfKckVNNcG2Bm","market":"us","size":263258},{"description":"","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231_g5.jpg","primary":false,"translateUrl":"","linkName":"mrna-20251231_g5.jpg","type":"GRAPHIC","id":"NTFILEFsk52z5kDL5KXWwy","market":"us","size":153784}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"年度报告","pubTime":"2026-02-20 13:00","pubTimestamp":1771563600,"title_zh":"Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20735003","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000015-MRNA","pdf_url":"","pub_time":1770958800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"MRNA","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/0001682852-26-000015-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/exhibit9912025q4pressrelea.htm","primary":true,"translateUrl":"","linkName":"exhibit9912025q4pressrelea.htm","type":"EX-99.1","id":"NTFILEBoT6stF5tfTMpHku","market":"us","size":164349},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/mrna-20260213.htm","primary":false,"translateUrl":"","linkName":"mrna-20260213.htm","type":"8-K","id":"NTFILEG6HNnB5K5r4TtjBX","market":"us","size":30069}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-02-13 13:00","pubTimestamp":1770958800,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20727446","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000012-MRNA","pdf_url":"","pub_time":1770764567000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"MRNA","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/0001682852-26-000012-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 7.01: Regulation FD Disclosure;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000012/exhibit991-02102026.htm","primary":true,"translateUrl":"","linkName":"exhibit991-02102026.htm","type":"EX-99.1","id":"NTFILE2TtKX4MQXKpzDfSu","market":"us","size":22481},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000012/mrna-20260203.htm","primary":false,"translateUrl":"","linkName":"mrna-20260203.htm","type":"8-K","id":"NTFILEDHFvyay5LL1njumf","market":"us","size":30131}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-02-11 07:02","pubTimestamp":1770764567,"title_zh":"Form 8-K - Current report","summary_en":"Item 7.01: Regulation FD Disclosure;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第7.01项：法规FD披露；项目8.01：其他事件；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20623780","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000007-MRNA","pdf_url":"","pub_time":1768194000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"MRNA","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000007/0001682852-26-000007-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000007/exhibit991-01122026.htm","primary":true,"translateUrl":"","linkName":"exhibit991-01122026.htm","type":"EX-99.1","id":"NTFILEBnB2rGdJF82dGMnA","market":"us","size":26335},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000007/mrna-20260112.htm","primary":false,"translateUrl":"","linkName":"mrna-20260112.htm","type":"8-K","id":"NTFILE9ETNDu2LQK9YPwb1","market":"us","size":31561}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-12 13:00","pubTimestamp":1768194000,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"项目2.02：经营业绩和财务状况；第7.01项：法规FD披露；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20600634","market":"us","labels":[],"media":"sec.gov","original_id":"AN168285226000003-MRNA","pdf_url":"","pub_time":1767589200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"MRNA","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/0001682852-26-000003-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/exhibit991-01052026lettert.htm","primary":true,"translateUrl":"","linkName":"exhibit991-01052026lettert.htm","type":"EX-99.1","id":"NTFILEGCohV7pXpQrK5ANk","market":"us","size":38442},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/mrna-20260105.htm","primary":false,"translateUrl":"","linkName":"mrna-20260105.htm","type":"8-K","id":"NTFILEE2gFnxMWkqAka4M4","market":"us","size":29802},{"description":"","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/image_0a.jpg","primary":false,"translateUrl":"","linkName":"image_0a.jpg","type":"GRAPHIC","id":"NTFILE2dNFW2WZyRSN15xT","market":"us","size":29394},{"description":"","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000003/imagea.jpg","primary":false,"translateUrl":"","linkName":"imagea.jpg","type":"GRAPHIC","id":"NTFILEEvPKsCEPFXAPzZy7","market":"us","size":2451}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-01-05 13:00","pubTimestamp":1767589200,"title_zh":"Form 8-K - Current report","summary_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第7.01项：法规FD披露；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.modernatx.com;www.investors.modernatx.com","stockEarnings":[{"period":"1week","weight":0.118},{"period":"1month","weight":0.0377},{"period":"3month","weight":0.2592},{"period":"6month","weight":0.9798},{"period":"1year","weight":1.1806},{"period":"ytd","weight":0.7932}],"compareEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":0.0881},{"period":"3month","weight":0.0682},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.31},{"period":"ytd","weight":0.0841}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Moderna, Inc.于2016年7月22日根据特拉华州法律注册成立。该公司是信使核糖核酸（信使核糖核酸）医学领域的领导者。通过在科学、技术和健康的交叉领域工作十多年，该公司以前所未有的速度和效率开发出药物，包括最早和最有效的新冠疫苗之一。该公司的mRNA平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗的开发成为可能。凭借独特的文化和由Moderna价值观和思维模式驱动的全球化团队，以负责任的方式改变人类健康的未来，该公司努力通过mRNA药物向人们传递尽可能大的影响。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.112326},{"month":2,"riseRate":0.375,"avgChangeRate":0.016129},{"month":3,"riseRate":0.5,"avgChangeRate":0.01856},{"month":4,"riseRate":0.625,"avgChangeRate":0.096502},{"month":5,"riseRate":0.625,"avgChangeRate":0.073299},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.025027},{"month":7,"riseRate":0.714286,"avgChangeRate":0.106584},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.089569},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.018964},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.032236},{"month":11,"riseRate":0.714286,"avgChangeRate":0.206001},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.033274}],"exchange":"NASDAQ","name":"Moderna, Inc.","nameEN":"Moderna, Inc."},"aProfile":null}}}